Alar Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
Alar Pharmaceuticals has been growing earnings at an average annual rate of 74.3%, while the Pharmaceuticals industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 156.5% per year. Alar Pharmaceuticals's return on equity is 15.9%, and it has net margins of 87.6%.
Key information
74.3%
Earnings growth rate
76.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | 156.5% |
| Return on equity | 15.9% |
| Net Margin | 87.6% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Alar Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 469 | 411 | 24 | 65 |
| 31 Dec 23 | 469 | 383 | 27 | 57 |
| 30 Sep 23 | 2 | -21 | 17 | 43 |
| 30 Jun 23 | 1 | -34 | 18 | 42 |
| 31 Mar 23 | 1 | -27 | 18 | 36 |
| 31 Dec 22 | 1 | -20 | 13 | 34 |
| 30 Sep 22 | 0 | -53 | 12 | 54 |
| 30 Jun 22 | 0 | -69 | 11 | 69 |
| 31 Mar 22 | 0 | -70 | 11 | 75 |
| 31 Dec 21 | 0 | -64 | 11 | 82 |
| 30 Sep 21 | 0 | -65 | 11 | 87 |
| 30 Jun 21 | 1 | -65 | 11 | 92 |
| 31 Mar 21 | 1 | -104 | 11 | 126 |
| 31 Dec 20 | 1 | -143 | 11 | 160 |
| 30 Sep 20 | 0 | -137 | 10 | 147 |
| 30 Jun 20 | 0 | -131 | 8 | 134 |
| 31 Mar 20 | 0 | -99 | 7 | 95 |
| 31 Dec 19 | 0 | -68 | 6 | 55 |
| 31 Dec 18 | 1 | -54 | 6 | 65 |
| 31 Dec 17 | 1 | -21 | 3 | 18 |
Quality Earnings: 6785 has high quality earnings.
Growing Profit Margin: 6785 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6785 has become profitable over the past 5 years, growing earnings by 74.3% per year.
Accelerating Growth: 6785 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 6785 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: 6785's Return on Equity (15.9%) is considered low.